NPS amends cinacalcet HCl license agreement with Amgen
According to the revised agreement, NPS will earn a one-time $25m payment in July 2012 in exchange for its rights to receive royalties under the license agreement that
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.